Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Cyclophosphamide 41Peripheral Blood Stem Cell Transplantation 40fludarabine phosphate 36Whole-Body Irradiation 27Mycophenolic Acid 27Tacrolimus 23Busulfan 23Cyclosporine 22Antilymphocyte Serum 20Etoposide 17Methotrexate 16Filgrastim 16Melphalan 14romidepsin 13Radiotherapy 13Flow Cytometry 12Methylprednisolone 10Brentuximab Vedotin 10Therapeutics 9Psychiatric Rehabilitation 9Lenalidomide 8pembrolizumab 7fludarabine 7Sirolimus 7Rituximab 7Bortezomib 7Bexarotene 7mogamulizumab 6Polymerase Chain Reaction 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Cutaneous × sintilimab × Clear all
NCT04296786 2020-03-05

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Peking Union Medical College Hospital

Phase 2 Unknown
52 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡